Assessing the Lyme Disease Diagnostic Market Size reveals an industry that is rapidly becoming a multi-billion dollar pillar of the infectious disease sector. With a 2025 valuation of USD 2.82 billion, the market's scale is a testament to the high volume of tests performed—estimated at over 30 million units annually in North America alone. The economic impact is further magnified by the high cost of advanced molecular diagnostics, which command premium pricing due to their specialized reagents and automated hardware requirements.

Investment in the sector is also being bolstered by "One Health" initiatives that link human, animal, and environmental health. Private equity firms are increasingly targeting diagnostic startups that focus on "Pan-Tick" panels—tests that can screen for a dozen different tick-borne pathogens in a single run. As healthcare systems look to reduce the long-term economic burden of chronic Lyme disease (estimated at billions in lost productivity), the value of early and accurate diagnostic tools is being recognized as a high-return investment for the global healthcare economy.

Related Reports